ReviewJournal of physiology and biochemistry2025
Effects and mechanisms of MSCs and MSC-derived exosomes in regulating ferroptosis.
Review in Journal of physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TRIM62 promotes osteoarthritis progression by facilitating GPX4 ubiquitination and chondrocyte ferroptosis.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ferroptosis is a kind of programmed cell death characterized by the iron-dependent lipid peroxides accumulation, playing a pivotal role in the pathogenesis of various diseases, including neurodegenerative disorders, cardiovascular diseases, and osteoporosis. Mesenchymal stem cells (MSCs) and MSCs-derived exosomes (MSC-exos) are actively implicated in key biological processes, such as inflammatory and immune responses, tissue regeneration and repair, and aging. Emerging studies highlight the potential of MSCs and MSC-exos as effective regulators of ferroptosis, offering novel strategies for targeted therapeutic intervention in ferroptosis-related pathologies. This review comprehensively explores the precise regulatory mechanisms by which MSCs and MSC-exos modulate ferroptosis. We also evaluate the impact of ferroptosis on MSC biological functions and MSC-exos release. Furthermore, the therapeutic potentials and advantages of engineered MSCs and MSC-exos in the treatment of various diseases have also been explored, emphasizing their mechanistic roles in ferroptosis modulation across different organs and systems. This review provides insights and future directions for the development of novel MSC- or MSC-exos-based therapeutic strategies targeting ferroptosis.
Indexed as
Identifiers
41118064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.